Clinical trial
Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis
NCT00333138 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00333138 |
|---|---|
| Title | Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis |
| Official title | Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Evaluating the Safety, Tolerability and Effect on MRI Lesion Parameters of FTY720 vs Placebo in Patients With Relapsing Multiple Sclerosis Including 18 Month Extension Phase |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | FTY720, Placebo |
| Enrollment | 281 |
| Start date | May 1, 2003 |
| Primary completion | Apr 1, 2011 |
| Completion | Apr 1, 2011 |
| First posted | Jun 2, 2006 |
| Last update posted | Sep 15, 2017 |
| Countries | Canada, Denmark, Finland, France, Germany, Italy, Poland, Portugal, Spain, Switzerland, United Kingdom |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: